Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taner Tan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Blood Research|December 2, 2024
How to improve AML outcomes?Taner Tan, Sinem Civriz Bozdag
Advances in Experimental Medicine and Biology|June 27, 2025
Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant CyclophosphamideTaner Tan, Zehra Narlı Özdemir, Sinem Civriz Bozdağ
British Journal of Haematology|June 17, 2025
Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohortUmut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|November 7, 2025
A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting TherapiesUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Cancer|December 30, 2025
Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patientsUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Blood Research|December 2, 2024
How to improve AML outcomes?Taner Tan, Sinem Civriz Bozdag
Advances in Experimental Medicine and Biology|June 27, 2025
Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant CyclophosphamideTaner Tan, Zehra Narlı Özdemir, Sinem Civriz Bozdağ
British Journal of Haematology|June 17, 2025
Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohortUmut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|November 7, 2025
A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting TherapiesUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Cancer|December 30, 2025
Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patientsUmut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, et al.
Pageof 1